The effect of tiotropium in the treatment of patients with COPD Source: Annual Congress 2010 - COPD: management Year: 2010
Acute bronchodilator response does not predict health outcomes in patients with COPD treated with tiotropium Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009
The bronchodilator response to salmeterol is maintained with regular, long-term use in patients with COPD Source: Eur Respir J 2002; 20: Suppl. 38, 240s Year: 2002
Dual bronchodilation with once-daily QVA149 reduces exacerbations, improves lung function and health status versus glycopyrronium and tiotropium in severe-to-very severe COPD patients: The SPARK study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013
Clinically important deteriorations in COPD as a measure of response to dual and mono bronchodilator therapy with and without inhaled corticosteroids Source: International Congress 2015 – New data on established treatments for COPD Year: 2015
Effects of tiotropium on neurohumoral activation during exercise in stable COPD patients Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009
Effects of adding salmeterol to inhaled corticosteroids on lung function and quality of life in patients with mild persistent asthma Source: Eur Respir J 2006; 28: Suppl. 50, 499s Year: 2006
Effect of glycopyrronium vs tiotropium on pulmonary function and morning symptoms in patients with moderate-to-severe COPD: The SPRING study Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015
Impact of adherence to treatment with tiotropium co-administered with fluticasone propionate/salmeterol combination in COPD patients Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease Year: 2013
The effects of adding in erdosteine on the routine bronchodilator therapy in moderate and severe COPD patients Source: Annual Congress 2006 - COPD therapy Year: 2006
Effect of exacerbation history and ICS use on outcomes in COPD patients from the TIOSPIR™ trial Source: International Congress 2015 – New data on established treatments for COPD Year: 2015
Are inhaled corticosteroids increasing the “load” for some patients with COPD? Source: Eur Respir J, 50 (4) 1701848; 10.1183/13993003.01848-2017 Year: 2017
Bronchodilator efficacy of tiotropium in patients with mild COPD Source: Eur Respir J 2006; 28: Suppl. 50, 616s Year: 2006
Short-acting bronchodilator reversibility does not predict the response to long-term treatment by indacaterol 150 µg in COPD: REVERBREZ study Source: Annual Congress 2013 –Respiratory and cardiovascular abnormalities in COPD: the role of exercise, nutritional status and inflammation Year: 2013
Smoking, sputum cell counts, diffusion capacity and hyperinflation predict beneficial effects of long-term inhaled corticosteroids (ICS) on FEV1-decline in patients with mild-to-moderate COPD Source: Annual Congress 2010 - COPD: management Year: 2010
Formoterol and tiotropium both improve lung function in stable COPD patients, with some additional benefit when given together Source: Eur Respir J 2006; 28: Suppl. 50, 429s Year: 2006
Increased respiratory symptoms in COPD patients on withdrawal of therapy: evidence of long-term efficacy gains with formoterol turbuhaler Source: Eur Respir J 2002; 20: Suppl. 38, 243s Year: 2002
Estimation of tiotropium efficacy at the COPD patients with group D Source: International Congress 2015 – Different data in COPD Year: 2015
Effects of acute dual bronchodilator treatment (tiotropium + olodaterol) on cardiopulmonary interactions in hyperinflated patients with COPD Source: International Congress 2018 – Advances in exercise physiopathology Year: 2018
Does an acute FEV1 response predict long-term improvements with bronchodilators in patients with COPD? Source: Eur Respir J 2001; 18: Suppl. 33, 486s Year: 2001